Investing Profile

Diyong Xu

InvestorVC
Partner (previously Principal-VP-Associate-Analyst) at OrbiMed
orbimed.comNew York, New York
Photo of Diyong Xu, Partner at OrbiMed

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Stanford University Network
1263 CONNECTIONS
Dartmouth College Network
233 CONNECTIONS
Lazard Network
120 CONNECTIONS
Bender Helper Impact Network
63 CONNECTIONS
OrbiMed Network
38 CONNECTIONS
cb
OrbiMed Partner
$1M - $75.0M
$4.0M
5
$18B
CompanyStageDateRound SizeTotal Raised
Q32 Bio
Post Ipo EquityMay 2026$55M
Post Ipo EquityMar 2024$42M
Series BOct 2020$60M
Series AMay 2020$46M
$200M
Co-investors: David Grayzel (Atlas Venture), Isaac Manke (Acorn Bioventures)
OnCusp Therapeutics
Series AJan 2024$100M
$100M
Co-investors: Chong Xu (F-Prime Capital Partners), Karen Hong (De Novo Ventures)
Private Equity Intern Bender Helper ImpactPresent
Private Equity Intern Flag Tree CapitalPresent
Investment Banking Intern Instream Partners LLCPresent
Investment Banking LazardPresent
Investment Banking Lazard Freres & Co.Present
Principal, Private Equity / Venture Capital OrbiMed AdvisorsPresent
Partner (previously Principal-VP-Associate-Analyst) OrbiMedPresent
Zhejiang University B.S. Biological Sciences
Dartmouth College M.S. Molecular and Cellular Biology
Stanford University M.S. Management Science and Engineering
Sign in with Google →
Sign in with Google →